期刊文献+

Survivin在慢性缺氧大鼠肺组织中的表达及意义 被引量:7

Expression of Survivin in pulmonary artery of rats exposed to normoxia and hypoxia
原文传递
导出
摘要 目的 探讨Survivin在慢性缺氧性肺动脉高压大鼠肺组织中的表达及意义.方法 将18只雄性Wistar大鼠随机分为对照组(N组)、缺氧4周组(H组)、缺氧4周+YM155组(小分子Survivin 拮抗剂,HY组),每组6只,观察YM155对大鼠肺动脉平均压(mPAP)、右心室质量(RV)和左心室+室间隔质量(LV+S)的影响;采用免疫组织化学的方法,观察Survivin在三组大鼠肺组织中的表达及分布特点;采用实时定量PCR方法分析三组大鼠肺组织中Survivin mRNA的表达水平.结果 ①经YM155处理后,缺氧组大鼠mPAP从(29.4±1.7) mm Hg降至(19.6±1.3) mm Hg(P<0.01),RV质量从(0.29±0.02)g降至(0.19±0.02)g(P<0.01).②N组大鼠,无论是近端肺动脉,还是远端肺动脉,Survivin均不表达.而在H组,Survivin在肺内小动脉(直径60~200 μm)呈高表达(P<0.01),且主要位于中膜,而在近端肺动脉,即中型肺动脉(200~500 μm)和大型肺动脉(500~1 000 μm),Survivin无明显表达.H组小型肺动脉Survivin的阳性表达强度(平均吸光度值,A值)较N组A值显著增加(N组:0.001 3±0.000 5 vs H组:0.268 3±0.023 9,P<0.01).YM155处理后,HY组大鼠肺内小肺动脉Survivin的表达强度(A值)明显减弱(H组:0.268 3±0.023 9 vs HY组:0.001 8±0.000 4).③H组大鼠肺组织Survivin mRNA表达水平明显高于N组大鼠(P<0.01),YM155处理后,HY组大鼠肺组织Survivin mRNA表达水平明显下降(P<0.01).结论 Survivin在慢性缺氧肺组织中高表达,且主要位于肺内小动脉的中膜,小分子Survivin拮抗剂YM155可以降低mPAP、减轻右心室肥厚,逆转肺动脉高压,从而揭示Survivin可能是肺动脉高压的治疗新靶位. Objective To clarify the roles of Survivin in the chronic hypoxic pulmonary hypertension (HPH),the expression of Survivin was investigated in rats.Methods Eighteen age and body weight matched male Wistar rats were randomly divided into control,chronic hypoxic group for 4 weeks and chronic hypoxic group for 4 weeks treated with YM155 group.YM155 dose of 6.5 mg/kg filled the Alzet penetration capsules pump,under sterile conditions,the pump was implanted in rat abdominal subcutaneous continuous administration of the first and second weeks of hypoxia implanted each capsules.The expression and distribution of Survivin were examined along the axial pathway of the pulmonary arteries of three group rats using immunohistochemical method,and Survivin mRNA expression of lung tissue of three group rats was analyzed by real-time polymerase chain reaction.Results After treating with YM155,mPAP of hypoxia rats was declined from (29.4±1.7)mm Hg to (19.6±1.3)mm Hg (P 〈0.01),and the weight of RV from (0.29±0.02)g to (0.19±0.02)g (P 〈0.01).In normal condition,Survivin was not expressed in the pulmonary arteries both in the proximal and distal segments.Following exposure to hypoxia,the distribution of Survivin localized predominated in the media of the distal segments of pulmonary artery,whereas Survivin was not almost expressed in the intima of the distal segments (P 〈0.01).After treating with YM155,the expression of Survivin was down-regulated,especially in the media of the distal segments of pulmonary artery after four weeks exposure to chronic hypoxia (P 〈0.01).Under normoxic condition,the mRNA expression of Survivin in rat pulmonary tissues was not detected,after 4 weeks hypoxia,the mRNA expression of Survivin in pulmonary tissues was significantly increase.When treated with YM155,the mRNA expression of Survivin in hypoxic rat pulmonary tissues was remarkable decrease from (27 989.55± 15 130.29) to (5 406.11± 1 554.20).Conclusions Survivin was highly expressed in the pulmonary arteries of rats exposed to chronic hypoxia,its distribution in the media was in the distal segments.YM155,a novel small-molecule Survivin suppressant,could not only down-regulate expression of Survivin in the distal pulmonary artery and lung tissue of rats exposed to chronic hypoxia,but also reduce mPAP and RVH,and reverse HPH of the rats.YM155 might potentially be a therapeutic agent for HPH.
出处 《国际呼吸杂志》 2013年第13期994-998,共5页 International Journal of Respiration
基金 国家自然科学基金资助项目(81170045)
关键词 缺氧 肺动脉高压 SURVIVIN Hypoxia Pulmonary artery hypertension Survivin
  • 相关文献

参考文献22

  • 1Weir EK, L6pez-Barneo J, Buckler KJ, et al. Acute oxygen- sensing mechanisms. N Engl J Med, 2005,353 : 2042-2055.
  • 2Jurasz P, Courtman D, Bahaie S, et al. Role of apoptosis in pulmonary hypertension:from experimental models to clinical trials. Pharmacol Ther, 2010,126 : 1-8.
  • 3Miehelakis ED, Wilkins MR, Rabinoviteh M. Emerging concepts and translational priorities in pulmonary arterial hypertension. Circulation,2008,118 : 1486-1495.
  • 4Ryan BM, O:Donovan N, Dully MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev, 2009,35:553-562.
  • 5Yang D, Welm A, Bishop JM. Cell division and cell survival in the absence of survivin. Proc Natl Acad Sci U S A, 2004, 101 : 15100-15105.
  • 6Altieri DC. Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer, 2008,8 : 61-70.
  • 7Iwasa T, Okamoto I, Takezawa K, et al. Marked anti- tumour activity of the combination of YM155, a novel survivin suppressant, and platinum-based drugs. Br J Cancer, 2010,103 : 36-42.
  • 8Nakahara T, Kita A, Yamanaka K,et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res, 2007,67 : 8014-8021.
  • 9Lewis KD, Samlowski W, Ward J, et al. A multi-center phase ]I evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage Ill or IV melanoma. Invest New Drugs, 2011,29 : 161-166.
  • 10薛全福,谢剑鸣.常压缺氧性大鼠肺动脉高压模型的建立[J].中华结核和呼吸杂志,1989,12(6):350-352. 被引量:157

共引文献240

同被引文献110

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部